OXFORD, UNITED KINGDOM--(Marketwire - June 27, 2011) -
Oxford Nanopore appoints Peter Allen as Non-Executive Director
Monday 27th June 2011, Oxford, UK. Oxford Nanopore Technologies Ltd is
pleased to announce the appointment of Peter Allen ACA to its board.
Peter Allen joins the board of Oxford Nanopore as non executive
Director with broad, senior experience in the life sciences industries.
He currently serves as Non-Executive Chairman on the Boards of
ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen
Previously, Peter was Chief Financial Officer of the electronics
company Abacus Group plc from April 2005 until the company was sold to
Avnet Inc in January 2009. Prior to this he was Chief Financial Officer
of Celltech Group plc between 1992 and 2004. In addition to managing
Celltech's flotation process in 1993, Peter played a key role in
several strategic acquisitions, including Chiroscience Group plc,
Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also
appointed Deputy Chief Executive Officer of Celltech until the company
was sold to UCB in 2004.
Oxford Nanopore also announces the retirement of Riccardo Pigliucci
from his role as non executive director, after serving nearly five
years on the board."We are excited to welcome Peter Allen to the Board of
Nanopore," said Dr Trevor Nicholls, Chairman of Oxford
Nanopore. "Peter's corporate and financial experience across science
and technology industries will add to the strength of our existing
board. We also extend our thanks to Riccardo Pigliucci for his years of
valuable service to the Company."
Dr Gordon Sanghera, CEO, added, "As Oxford Nanopore transitions to its
next stage of corporate development, Peter will provide invaluable
expertise along the pathway of a fast growth company with a genuinely
disruptive technology. We are looking forward to working with Peter in
this exciting period."
Contact: Zoe McDougall, Communications, Oxford Nanopore
Oxford Nanopore Technologies
Oxford Nanopore Technologies Ltd is developing a novel technology for
direct, electronic detection and analysis of single molecules using
nanopores. The modular, scalable GridION technology platform is
designed to offer substantial benefits in a variety of applications.
The Company is developing two techniques for DNA sequencing:
Exonuclease Sequencing and StrandSequencing, both of which combine a
protein nanopore with a processive enzyme for the analysis of DNA. The
system is also compatible with the direct analysis ofRNA. Oxford
Nanopore is also developing aProtein Analysistechnology that combines
target proteins with ligands for direct, electronic analysis using
protein nanopores. These nanopore sensing techniques are combined with
the Company's proprietary array chip within theGridIONsystem. The
Company also has collaborations for the development ofsolid-state
Oxford Nanopore has collaborations and exclusive licensing deals with
leading institutions including the University of Oxford, Harvard and
UCSC. The Company has funding programmes in these laboratories to
support the science of nanopore sensing. Oxford Nanopore has licensed
or owns more than 300 patents and patent applications that relate to
many aspects of nanopore sensing from protein nanopores to solid state
nanopores and for the analysis of DNA, proteins and other molecules.
This includes the use of functionalised solid-state nanopores for
molecular characterisation, methods of fabricating solid-state
nanopores and modifications of solid-state nanopores to adjust
sensitivity or other parameters.
This information is provided by RNS
The company news service from the London Stock Exchange